Pallidal beta bursts in Parkinson's disease and dystonia
Conclusions: Prolonged burst duration appears as a disease ‐specific feature for beta activity in PD across the basal ganglia. With dopaminergic medication, beta bursts in PD resemble those in dystonia, which supports the notion of short beta bursts as a physiological pattern. (Source: Movement Disorders)
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: Roxanne Lofredi,
Wolf ‐Julian Neumann,
Christof Brücke,
Julius Huebl,
Joachim K. Krauss,
Gerd‐Helge Schneider,
Andrea A. Kühn Tags: Brief Report Source Type: research
BDNF provides many routes toward STN DBS ‐mediated disease modification
AbstractThe concept that subthalamic nucleus deep brain stimulation (STN DBS) may be disease modifying in Parkinson's disease (PD) is controversial. Several clinical trials that enrolled subjects with late ‐stage PD have come to disparate conclusions on this matter. In contrast, some clinical studies in early‐ to midstage subjects have suggested a disease‐modifying effect. Dopaminergic innervation of the putamen is essentially absent in PD subjects within 4 years after diagnosis, indicating that any neuroprotective therapy, including STN DBS, will require intervention within the immediate postdiagnosis interval. Prec...
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: D. Luke Fischer,
Caryl E. Sortwell Tags: Scientific Perspectives Source Type: research
α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
Conclusions: CSF α‐synuclein species could be useful as part of a biomarker panel for dementia with Lewy bodies. Evaluating both oligomeric α‐synuclein and total α‐synuclein in CSF helps in the diagnosis of dementia with Lewy bodies. © 2018 The Authors.Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. (Source: Movement Disorders)
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: Inger Steenoven,
Nour K. Majbour,
Nishant N. Vaikath,
Henk W. Berendse,
Wiesje M. Flier,
Wilma D.J. Berg,
Charlotte E. Teunissen,
Afina W. Lemstra,
Omar M.A. El ‐Agnaf Tags: Research Article Source Type: research
Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model
Conclusions: A progressive and severe decline in somatodendritic morphology occurs prior to cell death, but is not responsible for the subtle decrements observable in the earliest stages of neurodegeneration. This work could help identify the ideal time window for specific treatments to halt disease progression and avert debilitating motor deficits in Parkinson's patients. © 2018 International Parkinson and Movement Disorder Society (Source: Movement Disorders)
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: William B. Lynch,
Christopher W. Tschumi,
Amanda L. Sharpe,
Sarah Y. Branch,
Cang Chen,
Guo Ge,
Senlin Li,
Michael J. Beckstead Tags: Research Article Source Type: research
Pallidal beta bursts in Parkinson's disease and dystonia
Conclusions: Prolonged burst duration appears as a disease ‐specific feature for beta activity in PD across the basal ganglia. With dopaminergic medication, beta bursts in PD resemble those in dystonia, which supports the notion of short beta bursts as a physiological pattern. (Source: Movement Disorders)
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: Roxanne Lofredi,
Wolf ‐Julian Neumann,
Christof Brücke,
Julius Huebl,
Joachim K. Krauss,
Gerd‐Helge Schneider,
Andrea A. Kühn Tags: Brief Report Source Type: research
BDNF provides many routes toward STN DBS ‐mediated disease modification
AbstractThe concept that subthalamic nucleus deep brain stimulation (STN DBS) may be disease modifying in Parkinson's disease (PD) is controversial. Several clinical trials that enrolled subjects with late ‐stage PD have come to disparate conclusions on this matter. In contrast, some clinical studies in early‐ to midstage subjects have suggested a disease‐modifying effect. Dopaminergic innervation of the putamen is essentially absent in PD subjects within 4 years after diagnosis, indicating that any neuroprotective therapy, including STN DBS, will require intervention within the immediate postdiagnosis interval. Prec...
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: D. Luke Fischer,
Caryl E. Sortwell Tags: Scientific Perspectives Source Type: research
α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
Conclusions: CSF α‐synuclein species could be useful as part of a biomarker panel for dementia with Lewy bodies. Evaluating both oligomeric α‐synuclein and total α‐synuclein in CSF helps in the diagnosis of dementia with Lewy bodies. © 2018 The Authors.Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. (Source: Movement Disorders)
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: Inger Steenoven,
Nour K. Majbour,
Nishant N. Vaikath,
Henk W. Berendse,
Wiesje M. Flier,
Wilma D.J. Berg,
Charlotte E. Teunissen,
Afina W. Lemstra,
Omar M.A. El ‐Agnaf Tags: Research Article Source Type: research
Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model
Conclusions: A progressive and severe decline in somatodendritic morphology occurs prior to cell death, but is not responsible for the subtle decrements observable in the earliest stages of neurodegeneration. This work could help identify the ideal time window for specific treatments to halt disease progression and avert debilitating motor deficits in Parkinson's patients. © 2018 International Parkinson and Movement Disorder Society (Source: Movement Disorders)
Source: Movement Disorders - November 15, 2018 Category: Neurology Authors: William B. Lynch,
Christopher W. Tschumi,
Amanda L. Sharpe,
Sarah Y. Branch,
Cang Chen,
Guo Ge,
Senlin Li,
Michael J. Beckstead Tags: Research Article Source Type: research
Glial GLP1R: A novel neuroprotector?
Movement Disorders, EarlyView. (Source: Movement Disorders)
Source: Movement Disorders - November 14, 2018 Category: Neurology Authors: Aubrey M. Schonhoff,
Ashley S. Harms Tags: Hot Topics Source Type: research
Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus
Movement Disorders, EarlyView. (Source: Movement Disorders)
Source: Movement Disorders - November 14, 2018 Category: Neurology Authors: Norlinah Mohamed Ibrahim,
Roshila Ramli,
Shahedah Koya Kutty,
Shamsul Azhar Shah Tags: Letters: New Observations Source Type: research
Glial GLP1R: A novel neuroprotector?
Movement Disorders, EarlyView. (Source: Movement Disorders)
Source: Movement Disorders - November 14, 2018 Category: Neurology Authors: Aubrey M. Schonhoff,
Ashley S. Harms Tags: Hot Topics Source Type: research
Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus
Movement Disorders, EarlyView. (Source: Movement Disorders)
Source: Movement Disorders - November 14, 2018 Category: Neurology Authors: Norlinah Mohamed Ibrahim,
Roshila Ramli,
Shahedah Koya Kutty,
Shamsul Azhar Shah Tags: Letters: New Observations Source Type: research
Life span pigmentation changes of the substantia nigra detected by neuromelanin ‐sensitive MRI
Conclusions: Using optimized neuromelanin MRI in a life span sample, we demonstrate a strong age effect with inverted U ‐shaped SNpc pigmentation‐related contrast from childhood to old age. This age trajectory of physiological SNpc pigmentation needs to be taken into account for diagnostic applications of depigmentation. The study also paves the way for systematic investigations of the mechanisms of neuromelanin in healthy and pathological brain development and aging. © 2018 International Parkinson and Movement Disorder Society (Source: Movement Disorders)
Source: Movement Disorders - November 13, 2018 Category: Neurology Authors: Yue Xing,
Abdul Sapuan,
Rob A. Dineen,
Dorothee P. Auer Tags: Research Article Source Type: research
Sensing α‐Synuclein From the Outside via the Prion Protein: Implications for Neurodegeneration
AbstractParkinson's disease and other synucleinopathies are characterized by the accumulation of aggregated α‐synuclein in intracellular proteinaceous inclusions. The progressive nature of synucleinopathies seems to be related to the cell‐to‐cell spreading of α‐synuclein pathology, and several possible mechanisms have been put forward to explain this phenomenon. In our recent study, we found tha t α‐synuclein oligomers interact with cellular prion protein in glutamatergic synapses. This interaction triggered a signaling cascade involving phosphorylation of Fyn kinase and activation of the N‐methyl‐d‐aspa...
Source: Movement Disorders - November 13, 2018 Category: Neurology Authors: In ês Caldeira Brás,
Luísa V. Lopes,
Tiago Fleming Outeiro Tags: Scientific Perspectives Source Type: research
